"Chari Considers Choosing Proteasome Inhibitors in Relapsed Multiple Myeloma"
Ajai Chari, MD, associate professor, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai discusses the treatment options available to patients with relapsed multiple myeloma. “Although the SWOG study showed that bortezomib, lenalidomide, and dexamethasone were superior to lenalidomide plus dexamethasone—ie, triplets are better than doublets, which I think is well understood in practice—the question that is being asked now is: Should carfilzomib, the more potent proteasome inhibitor, be used in frontline therapy?” He added, “It is important to note that that was just the PI and dexamethasone. When we add an IMID [immunomodulatory drug], it is not recommended to give a dose higher than 36 mg/m.”
— Ajai Chari, MD, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Associate Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Mount Sinai’s Staten Island Cancer Center Moves to New Site
Nov 09, 2023 View All Press ReleasesDiabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race
Sep 29, 2023 View All Press ReleasesResearchers Find Treatment Options for Patients Whose Blood Cancer Relapses After CAR-T
Nov 04, 2022 View All Press ReleasesStudy Identifies New Gene That Drives Colon Cancer
Oct 14, 2022 View All Press ReleasesMount Sinai Researchers Discover Genes That Predict Good Response to Blood Cancer Therapy
Jun 16, 2022 View All Press ReleasesMount Sinai Receives Grant to Enhance Patient-Centric, Team-Based Pancreatic Cancer Care
Apr 19, 2022 View All Press Releases